Thomas J. Rutkoski, Ph.D.
Affiliations: | 2008 | University of Wisconsin, Madison, Madison, WI |
Area:
Chemical biology, protein design and engineering, enzymology, biofuelsGoogle:
"Thomas Rutkoski"Parents
Sign in to add mentor| Ronald T. Raines | grad student | 2008 | UW Madison | |
| (Engineering ribonuclease-based cancer therapeutics) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Smith BD, Kaufman MD, Lu WP, et al. (2019) Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell. 35: 738-751.e9 |
| Cortes J, Talpaz M, Smith HP, et al. (2016) Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica |
| Smith BD, Kaufman MD, Leary CB, et al. (2015) Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2. Molecular Cancer Therapeutics. 14: 2023-34 |
| Henry JR, Kaufman MD, Peng SB, et al. (2015) Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells. Journal of Medicinal Chemistry. 58: 4165-79 |
| Smith BD, Hood MM, Wise SC, et al. (2015) Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models Cancer Research. 75: 2690-2690 |
| Moon S, Bannen RM, Rutkoski TJ, et al. (2014) Effectiveness and limitations of local structural entropy optimization in the thermal stabilization of mesophilic and thermophilic adenylate kinases. Proteins. 82: 2631-42 |
| Rutkoski TJ, Kink JA, Strong LE, et al. (2013) Human ribonuclease with a pendant poly(ethylene glycol) inhibits tumor growth in mice. Translational Oncology. 6: 392-7 |
| Bianchetti CM, Brumm P, Smith RW, et al. (2013) Structure, dynamics, and specificity of endoglucanase D from Clostridium cellulovorans. Journal of Molecular Biology. 425: 4267-85 |
| Rutkoski TJ, Kink JA, Strong LE, et al. (2011) Site-specific PEGylation endows a mammalian ribonuclease with antitumor activity. Cancer Biology & Therapy. 12: 208-14 |
| Chan WW, Wise SC, Kaufman MD, et al. (2011) Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 19: 556-68 |